Markus F. Herzig

78 year

Health Technology

Profile

Markus F.
Herzig has been Vice President of Regulatory Affairs for Allos Therapeutics, Inc. since August 2001.
Previously, he was Executive Director of Regulatory Affairs and Quality Assurance for OraPharma, Inc. from January 1999 to August 2001.
From January 1986 to December 1998, Mr. Herzig held management positions at Takeda Pharmaceuticals America, Inc., Novo Nordisk Pharmaceuticals, Inc., Organon, Inc. and Sandoz Pharmaceuticals Corp.
He received an MS degree from Allgemeine Gewerbe Schule in Basel, Switzerland.

Former positions of Markus F. Herzig

Companies	Position	End
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	General Counsel	-

See the detail of Markus F. Herzig's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies